跳至主要内容
临床试验/NCT00214123
NCT00214123已完成1 期

The Use of Helical Tomotherapy to Achieve Dose-per-fraction Escalation in Lung Cancer

University of Wisconsin, Madison2 个研究点 分布在 1 个国家目标入组 79 人开始时间: 2004年6月最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
入组人数
79
试验地点
2
主要终点
Grade 3 pneumonitis lasting greater than 2 weeks

研究概览

简要总结

The purpose of this trial is to pilot reducing the duration of radiation treatment for lung cancer patients from 6 to 5 weeks using tomotherapy. Specific patient doses will be based on tumor volume being treated. Modeling has shown that increased biologically effective dose (BED) to tumors can be achieved by shortening the radiation delivery schedule and increasing the dose per fraction. This requires decreasing the total dose to hold lung toxicity constant at each dose per fraction level. This is a major paradigm shift in the treatment in this disease and is projected to result in significant improvements in patient outcome as well as a substantial cost savings.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Thoracic neoplasm requiring at lest 60 Gy conventional radiotherapy

排除标准

  • Prior bleomycin or gemcitabine chemotherapy
  • Prior thoracic radiotherapy

结局指标

主要结局

Grade 3 pneumonitis lasting greater than 2 weeks

时间窗: 90 days post radiotherapy (XRT)

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验